Biotech News
GSK and Empirico enter license agreement for clinical-stage, first-in-class oligonucleotide candidate to treat respiratory diseases
siRNA candidate EMP-012 in phase I for treatment of COPD.
Related news
CHRSCoherus BioSciences, Inc.2026-06-23 18:00 EST
Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)
GSKGSK plc2026-07-17 09:00 EST
GSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC)
GSKGSK plc2026-07-28 12:00 EST
GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026
IDYAIDEAYA Biosciences2026-06-03 10:00 EST
IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer
BMYBMYBristol-Myers Squibb Company2026-07-20 10:59 EST
Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA
BMYBMYBristol-Myers Squibb Company2026-06-08 10:59 EST
Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease
BMEABiomea Fusion2026-06-03 12:00 EST
Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity
ENTAEnanta Pharmaceuticals2026-06-18 11:00 EST
Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)
TEVATeva Pharmaceutical Industries2026-07-09 12:30 EST
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
LEGNLegend Biotech Corporation2026-06-15 12:00 EST
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
GSK plc
Global Biopharmaceutical Portfolio GSK is a global biopharmaceutical company operating across Specialty Medicines, Vaccines, and General Medicines. Its commercial portfolio spans HIV, oncology, respiratory and immuno-inflammation, vaccines, and established medicines, supported by a growing late-stage pipeline and externally sourced...
Recent company news
GSKGSK plc2026-07-29 09:08 EST
Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026
GSKGSK plc2026-07-28 12:05 EST
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSKGSK plc2026-07-28 12:00 EST
GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026
GSKGSK plc2026-07-28 11:00 EST
GSK’s licensor Hansoh Pharma announces positive results from a second phase III trial for Ris-Rez in China
GSKGSK plc2026-07-27 14:55 EST
ViiV Healthcare’s 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy in first-of-its-kind head-to-head study in treatment-naïve adults living with HIV
Stock data
- Close
- 52.17 USD
- Market cap
- 98.26B USD
- Exchange
- NYSE
- Sector
- Vaccines, Biopharma, Gene Therapy, Antibody Drugs, Small Molecule Drugs, Nucleic Acid Drugs
- Location
- United States